| Title |
When to Start Antiretroviral Therapy
|
|---|---|
| Published in |
Current HIV/AIDS Reports, April 2010
|
| DOI | 10.1007/s11904-010-0044-6 |
| Pubmed ID | |
| Authors |
Vivek Jain, Steven G. Deeks |
| Abstract |
The question of when to start combination antiretroviral therapy for treatment-naïve patients has always been controversial. This is particularly true in the current era, with major guidelines recommending very different treatment strategies. Despite a lack of clarity regarding the optimal time to begin therapy, there has been a recent shift toward earlier initiation. This more aggressive approach is driven by several observations. First, effective viral suppression with therapy can prevent non-AIDS-related morbidity and mortality. Second, therapy can prevent irreversible harm to the human immune system. Third, therapy may prevent transmission of HIV to others, and thus have a potential public health benefit. For patients who are motivated and willing to initiate early treatment, the collective benefits of early therapy may outweigh the well-documented risks of antiretroviral medications. |
Mendeley readers
The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 2% |
| Kenya | 1 | 2% |
| Unknown | 40 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 7 | 17% |
| Student > Master | 7 | 17% |
| Researcher | 6 | 14% |
| Professor > Associate Professor | 4 | 10% |
| Student > Bachelor | 3 | 7% |
| Other | 7 | 17% |
| Unknown | 8 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 19 | 45% |
| Agricultural and Biological Sciences | 3 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
| Nursing and Health Professions | 2 | 5% |
| Business, Management and Accounting | 2 | 5% |
| Other | 7 | 17% |
| Unknown | 7 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 March 2014.
All research outputs
#4,597,999
of 23,313,051 outputs
Outputs from Current HIV/AIDS Reports
#98
of 437 outputs
Outputs of similar age
#19,661
of 96,105 outputs
Outputs of similar age from Current HIV/AIDS Reports
#3
of 4 outputs
Altmetric has tracked 23,313,051 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 437 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 96,105 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one.